share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian

CRISPR Therapeutics | 3:首次持股聲明-董事 Rommel Christian
美股SEC公告 ·  05/30 16:34

Moomoo AI 已提取核心訊息

Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
CRISPR Therapeutics的董事兼10%所有者克里斯蒂安·隆美爾於2024年5月30日向美國證券交易委員會提交了初步的證券實益擁有權聲明。表格3申報是1934年《證券交易法》第16(a)條的要求,表明隆美爾不以實益方式擁有公司的任何非衍生或衍生證券。該表格是作爲個人而不是聯合/團體文件提交的,包括隆美爾的簽名和提交日期。
CRISPR Therapeutics的董事兼10%所有者克里斯蒂安·隆美爾於2024年5月30日向美國證券交易委員會提交了初步的證券實益擁有權聲明。表格3申報是1934年《證券交易法》第16(a)條的要求,表明隆美爾不以實益方式擁有公司的任何非衍生或衍生證券。該表格是作爲個人而不是聯合/團體文件提交的,包括隆美爾的簽名和提交日期。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息